Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Steve_Chapman
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:founded |
2004
|
| gptkbp:founder |
gptkb:Jonathan_Sheena
gptkb:Steve_Chapman gptkb:Matthew_Rabinowitz |
| gptkbp:headquartersLocation |
gptkb:Austin,_Texas,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
genetic testing |
| gptkbp:numberOfEmployees |
over 2,000
|
| gptkbp:product |
gptkb:Signatera
gptkb:Panorama gptkb:Horizon gptkb:Prospera |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:revenue |
$820 million (2023)
|
| gptkbp:specializesIn |
non-invasive prenatal testing
cancer monitoring cell-free DNA testing organ transplant rejection assessment |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:NTRA
|
| gptkbp:website |
https://www.natera.com/
|
| gptkbp:bfsParent |
gptkb:Casdin_Capital
gptkb:Roelof_Botha gptkb:San_Carlos,_California,_USA gptkb:San_Carlos,_California,_United_States gptkb:Sofinnova_Investments gptkb:Sutter_Hill_Ventures |
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Natera
|